Preclinical studies support their role in TNBC, demonstrating that PD-1 and PD-L1 inhibitors can effectively activate immune cells and enhance their ability to specifically kill TNBC cells, significantly inhibiting tumor growth [36]. Here, PDCD1 is linked to neoplasm.